CMPS COMPASS Pathways Plc

35.8
-1.36  -4%
Previous Close 37.16
Open 37.66
52 Week Low 22.51
52 Week High 61.69
Market Cap $1,312,708,994
Shares 36,667,849
Float 36,667,849
Enterprise Value $1,172,250,268
Volume 274,793
Av. Daily Volume 419,468
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Psilocybin
Treatment Resistant Depression
Phase 2b
Phase 2b
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Latest News

  1. London, UK, April 09, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (NASDAQ:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that George Goldsmith, Chairman, CEO and Co‑founder, and Lars Wilde, President, Chief Business Officer, and Co‑founder, will present a corporate update at 8:00am ET on 15 April at the 20th Annual Needham Virtual Healthcare Conference. Members of the COMPASS management team will also be holding 1:1 investor meetings.  

    A live audio webcast of the presentation will be available on the "Events" page of the Investors section of the COMPASS website. A replay of the webcast will be available for 30 days following the event. For…

    London, UK, April 09, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (NASDAQ:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that George Goldsmith, Chairman, CEO and Co‑founder, and Lars Wilde, President, Chief Business Officer, and Co‑founder, will present a corporate update at 8:00am ET on 15 April at the 20th Annual Needham Virtual Healthcare Conference. Members of the COMPASS management team will also be holding 1:1 investor meetings.  

    A live audio webcast of the presentation will be available on the "Events" page of the Investors section of the COMPASS website. A replay of the webcast will be available for 30 days following the event. For more information, please visit ir.compasspathways.com.

    -Ends-

    About COMPASS Pathways

    COMPASS Pathways plc (NASDAQ:CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, USA. Our vision is a world of mental wellbeing. www.compasspathways.com

     

    Contacts:

     

    Media: Tracy Cheung, , +44 7966 309024

    Investors: Stephen Schultz, , +1 401-290-7324

     

     

    Attachment



    Primary Logo

    View Full Article Hide Full Article


  2. COMPASS Pathways appoints Wayne J Riley MD to its Board of Directors

    London, UK – 1 April 2021        

    COMPASS Pathways plc (NASDAQ:CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has appointed Wayne J Riley MD to its Board of Directors.

    Dr Riley is President of the State University of New York (SUNY) Downstate Health Sciences University, Brooklyn, where he holds tenured professorships in internal medicine, and health policy and management. A primary care physician and an academic, he has more than 25 years of experience encompassing clinical and academic medicine, research programme oversight, biotechnology, primary care…





    COMPASS Pathways appoints Wayne J Riley MD to its Board of Directors

    London, UK – 1 April 2021        



    COMPASS Pathways plc (NASDAQ:CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has appointed Wayne J Riley MD to its Board of Directors.

    Dr Riley is President of the State University of New York (SUNY) Downstate Health Sciences University, Brooklyn, where he holds tenured professorships in internal medicine, and health policy and management. A primary care physician and an academic, he has more than 25 years of experience encompassing clinical and academic medicine, research programme oversight, biotechnology, primary care, public health, healthcare management and policy, healthcare quality, academic health science centre administration, and government service.

    "We are delighted to welcome Wayne to the COMPASS Board," said George Goldsmith, CEO and Co-founder of COMPASS Pathways. "He has dedicated his career to patients and to improving healthcare services. At COMPASS, we want to transform the patient experience in mental health care and to give people options. We look forward to benefitting from Wayne's breadth of expertise as we continue to advance our evidence-based research and to work towards our vision of a world of mental wellbeing."

    Dr Riley said, "I am honoured to join the Board of COMPASS Pathways at this critical time when it is more important than ever to develop novel, effective treatments for depression and other mental health conditions. I look forward to working with the Board and the management team and contributing to advancing COMPASS's quest to improve the lives of millions of patients worldwide."

    In addition to his position at SUNY Downstate Health Sciences University, Dr Riley is also Chairman of the Board of the New York Academy of Medicine, an elected member of the US National Academy of Medicine, a Commissioner of the US Medicare Payment Advisory Commission, and President of the Society of Medical Administrators. He is a President Emeritus of the American College of Physicians (ACP).

    Dr Riley is a member of the Board of Directors of HCA Healthcare Inc, a learning health system comprising 180 hospitals and more than 2,000 sites of care in the US and in the UK, where he serves as Chair of the Patient Safety & Quality Committee and a member of the Audit & Compliance and Nominating & Corporate Governance Committees. He previously served as a Director of Vertex Pharmaceuticals. He holds a BA from Yale University, an MPH from the Tulane University School of Public Health and Tropical Medicine, an MD from the Morehouse School of Medicine, and an MBA from Rice University.

    -Ends-

    About COMPASS Pathways

    COMPASS Pathways plc (NASDAQ:CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, US. Our vision is a world of mental wellbeing. www.compasspathways.com

    Availability of other information about COMPASS Pathways

    Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.  



    Forward-looking statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology such as "may", "might", "will", "could", "would", "should", "expect", "intend", "plan", "objective", "anticipate", "believe", "contemplate", "estimate", "predict", "potential", "continue" and "ongoing," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things, COMPASS's business strategy and goals, COMPASS's ability to continue to advance its research, and COMPASS's expectations regarding the benefits of its psilocybin therapy. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond COMPASS's control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements.

    These risks, uncertainties, and other factors include, among others: preclinical research and clinical development is lengthy and uncertain, and therefore our preclinical studies and clinical trials may be delayed or terminated, or may never advance to or in the clinic; and those risks and uncertainties described under the heading "Risk Factors" in COMPASS's annual report on Form 20-F filed with the US Securities and Exchange Commission (SEC) on 9 March 2021 and in subsequent filings made by COMPASS with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, COMPASS disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on COMPASS's current expectations and speak only as of the date hereof.          



    Enquiries



    Media: Tracy Cheung, , +44 7966 309024

    Investors: Stephen Schultz, , +1 401 290 7423

     



    Primary Logo

    View Full Article Hide Full Article

  3. COMPASS Pathways granted two US patents

    London, UK – 23 March 2021    

    COMPASS Pathways plc (NASDAQ:CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted two new patents by the US Patent and Trademark Office (USPTO). These patents cover oral formulations of COMPASS's synthetic psilocybin in the treatment of major depressive disorder (MDD), which includes treatment-resistant depression (TRD).

    US Patent No 10,954,259 was granted on 23 March 2021, with claims to COMPASS's high-purity crystalline psilocybin (including the form used in its synthetic formulation, COMP360), pharmaceutical formulations containing crystalline…



    COMPASS Pathways granted two US patents

    London, UK – 23 March 2021    



    COMPASS Pathways plc (NASDAQ:CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted two new patents by the US Patent and Trademark Office (USPTO). These patents cover oral formulations of COMPASS's synthetic psilocybin in the treatment of major depressive disorder (MDD), which includes treatment-resistant depression (TRD).

    US Patent No 10,954,259 was granted on 23 March 2021, with claims to COMPASS's high-purity crystalline psilocybin (including the form used in its synthetic formulation, COMP360), pharmaceutical formulations containing crystalline psilocybin and methods of treating MDD with the crystalline psilocybin.

    US Patent No 10,947,257 was granted on 16 March 2021, with claims to oral dosage forms of crystalline psilocybin and methods of treating MDD with the oral dosage forms.

    "These patents are a critical milestone in our efforts to establish a new evidence-based option to help patients with depression in the US," said George Goldsmith, CEO and Co-founder of COMPASS Pathways. "Through these grants, the USPTO has recognised our innovations. These decisions enable us to continue to do the highest quality clinical research and bring potentially life-changing care to patients who might benefit from this therapy."

    COMPASS's first US patent, No 10,519,175, was granted in December 2019 and covers the use of formulations of COMPASS's high-purity crystalline psilocybin in psilocybin therapy for patients with TRD.

    COMP360 is being investigated in a phase IIb clinical trial of psilocybin therapy for TRD. COMPASS received Breakthrough Therapy designation from the US FDA for this application in 2018. Data from the phase IIb trial is expected in late 2021.



    -Ends-

    About COMPASS Pathways

    COMPASS Pathways plc (NASDAQ:CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, US. Our vision is a world of mental wellbeing. www.compasspathways.com



    Availability of other information about COMPASS Pathways

    Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.  



    Forward-looking statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology such as "may", "might", "will", "could", "would", "should", "expect", "intend", "plan", "objective", "anticipate", "believe", "contemplate", "estimate", "predict", "potential", "continue" and "ongoing," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things, COMPASS's business strategy and goals, the benefits of additional patent protection to help achieve these goals, and COMPASS's expectations regarding the benefits of its psilocybin therapy. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond COMPASS's control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements.

    These risks, uncertainties, and other factors include, among others: preclinical research and clinical development is lengthy and uncertain, and therefore our preclinical studies and clinical trials may be delayed or terminated, or may never advance to or in the clinic; and those risks and uncertainties described under the heading "Risk Factors" in COMPASS's annual report on Form 20-F filed with the US Securities and Exchange Commission (SEC) on 9 March 2021 and in subsequent filings made by COMPASS with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, COMPASS disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on COMPASS's current expectations and speak only as of the date hereof.          



    Enquiries



    Media: Tracy Cheung, , +44 7966 309024

    Investors:
    Stephen Schultz, , +1 401 290 7423



    Primary Logo

    View Full Article Hide Full Article
    • Phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD) on track to report data by end of 2021
    • First Centre of Excellence, a research facility and innovation lab, established at Sheppard Pratt (Baltimore, Maryland, US)
    • Discovery Center expanded into network of world-leading scientists developing new optimised psychedelic compounds
    • Conference call today at 1.00pm GMT (8.00am ET)

    LONDON, March 09, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (NASDAQ:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and year-end 2020 and gave an update on recent progress across its business…

    • Phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD) on track to report data by end of 2021
    • First Centre of Excellence, a research facility and innovation lab, established at Sheppard Pratt (Baltimore, Maryland, US)
    • Discovery Center expanded into network of world-leading scientists developing new optimised psychedelic compounds
    • Conference call today at 1.00pm GMT (8.00am ET)

    LONDON, March 09, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (NASDAQ:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and year-end 2020 and gave an update on recent progress across its business.

    George Goldsmith, Chairman, CEO and Co-founder, COMPASS Pathways, said, "Mental health is an urgent crisis and this has only been exacerbated by the COVID-19 pandemic. At COMPASS we remain committed to transforming mental health care and helping patients who are suffering and aren't helped by existing treatments. Our phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression is actively recruiting and we plan to report data from this trial at the end of the year. We are also continuing preclinical research into new indications, new compounds and new technologies, working with partners through our Centre of Excellence, our Discovery Center, and a number of investigator-initiated studies, as well as developing a strong team."

    Business highlights

    • Continued progress with phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD)        

      - On track to report data end of 2021

      - New site added in London, UK, bringing trial to 22 sites in 10 countries

      - Working closely with all sites to assess the ongoing COVID-19 situation and COMPASS will always prioritise the safety of patients and teams

      - Paper on therapist training programme published in Frontiers in Psychiatry in February, setting out formal and scalable methodology for psychological support in psilocybin therapy

      - Breakthrough Therapy designation awarded by US FDA in 2018
    • Signal-generating, exploratory psilocybin therapy research underway in a range of indications

      - COMPASS has the right to exclusively license new IP generated through these investigator-initiated studies



    • Launch of first Centre of Excellence at Sheppard Pratt, Baltimore

      - Centres of Excellence are research facilities and innovation labs that COMPASS anticipates will model the "clinic of the future", showcasing the most advanced thinking in science, therapy, technology and design

      - Centres of Excellence should generate evidence to shape therapy models in mental health care, train and certify therapists, conduct clinical trials including proof-of-concept studies, and prototype digital solutions to improve patient experience

      - Initial research focused on COMP360 psilocybin therapy, which is already being used in two investigator-initiated studies looking at severe treatment-resistant depression and bipolar type II depression



    • Expansion of Discovery Center in the US

      - Discovery Center expanded beyond initial sponsored research agreement with University of the Sciences (Philadelphia, PA) to include collaborations with world-leading scientists from laboratories at UC San Diego, School of Medicine, and Medical College of Wisconsin, in a virtual network

      - Focus on development of new optimised psychedelic compounds targeting the 5-HT2A receptor

      - COMPASS is exclusive licensee for all new compounds generated



    Financial highlights

    • Net loss for the three months ended 31 December 2020 was $18.8 million, or $0.52 loss per share (after including non-cash share-based compensation expense of $1.4 million), compared with $7.6 million, or $0.90 loss per share, during the same period in 2019 (after including non-cash share-based compensation expense of $0.8 million)



    • The net loss for the 12 months ended 31 December 2020 was $60.3 million, or $3.55 loss per share (after including non-cash share-based compensation expense of $18.0 million), compared with $19.6 million, or $2.62 loss per share, during the same period in 2019 (after including non-cash share-based compensation expense of $3.3 million)



    • Research & development expenses (R&D) were $4.5 million for the three months ended 31 December 2020, compared with $4.6 million during the same period in 2019. R&D expenses were $23.4 million for the 12 months ended 31 December 2020, compared with $12.6 million during the same period in 2019, reflecting increased investment in the ongoing phase IIb COMP360 psilocybin therapy clinical programme for TRD



    • General and administrative expenses (G&A) were $7.0 million for the three months ended 31 December 2020, compared with $2.8 million during the same period in 2019. Of the increase, $0.5 million was related to share-based compensation expenses. G&A expenses were $28.0 million for the 12 months ended 31 December 2020, compared with $8.6 million during the same period in 2019. Of this increase, $10.2 million was related to share-based compensation expenses



    • Cash and cash equivalents were $190.3 million as of 31 December 2020, compared with $196.5 million at 30 September 2020



    Conference call

    The COMPASS Pathways management team will host a conference call at 1.00pm GMT (8.00am ET) on 9 March 2021. The call can be accessed by dialling (833) 665-0659 from the United States, +1 (914) 987-7313 internationally, and 0800 028 8438 from the UK, followed by the conference ID: 5558345.

    The call will also be webcast on the investors section of the COMPASS Pathways website (ir.compasspathways.com) and archived for 30 days.

    About COMPASS Pathways

    COMPASS Pathways plc (NASDAQ:CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, US. Our vision is a world of mental wellbeing. www.compasspathways.com        



    Availability of other information about COMPASS Pathways

    Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.        



    Forward-looking statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology such as "may", "might", "will", "could", "would", "should", "expect", "intend", "plan", "objective", "anticipate", "believe", "contemplate", "estimate", "predict", "potential", "continue" and "ongoing," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things, COMPASS's business strategy and goals, and COMPASS's expectations regarding its ongoing preclinical work and clinical trials, including the timing of the release of clinical data. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond COMPASS's control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements.

    These risks, uncertainties, and other factors include, among others: preclinical and clinical development is lengthy and uncertain, and therefore our preclinical studies and clinical trials may be delayed or terminated, or may never advance to or in the clinic; and those risks and uncertainties described under the heading "Risk Factors" in COMPASS's annual report on Form 20-F filed with the US Securities and Exchange Commission (SEC) on 9 March 2021 and in subsequent filings made by COMPASS with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, COMPASS disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on COMPASS's current expectations and speak only as of the date hereof.        

    Enquiries



    Media: Tracy Cheung, , +44 7966 309024

    Investors: Stephen Schultz, , +1 401 290 7423

    COMPASS PATHWAYS PLC

    Consolidated Balance Sheets

    (in thousands, except share and per share amounts)

    (expressed in US Dollars, unless otherwise stated

     September

    30, 2020
    December

    31, 2020
    December

    31, 2019
    ASSETS   
    CURRENT ASSETS:   
    Cash$ 196,505$ 190,327$ 24,966
    Restricted Cash292918
    Prepaid expenses and other current assets10,67112,0487,187
    Total current assets207,205202,40432,171
    Investments500529-
    Property and equipment, net231245218
    Other assets59570
    Total assets$ 207,995$ 203,456$ 32,389
    LIABILITIES, CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' DEFICIT   
    CURRENT LIABILITIES:   
    Accounts payable$ 2,630$ 2,739        $ 1,262
    Accounts payable - due to related party13863
    Accrued expenses and other liabilities2,2774,1481,457
    Convertible notes payable--12,397
    Convertible notes payable – due to related party--8,692
    Total current liabilities4,9206,89523,871
    Total liabilities4,9206,89523,871
    Commitments and contingencies   
    Convertible preferred shares, £0.008 par value; no shares authorized, issued and outstanding at September 30 and December 31, 2020; 9,782,506 shares authorized, issued and outstanding at December 31, 2019; aggregate liquidation preference of $39,279 at December 31, 2019--38,908
    SHAREHOLDERS' EQUITY (DEFICIT):   
    Ordinary shares, £0.008 par value; 35,930,331 shares authorized, issued an outstanding at September 30, 2020 and December 31, 2020; 10,752,429 shares authorized, issued an outstanding at December 31, 2019367367111
    Deferred shares, £21,921.504 par value; one share authorized, issued and outstanding at September 30, 2020 and December 31, 2020; no shares authorized, issued and outstanding at December 31, 20192828-
    Additional paid-in capital278,098279,4807,162
    Accumulated other comprehensive income (loss)3,67514,585(98)
    Accumulated deficit(79,093)(97,899)(37,565)
    Total shareholders' equity (deficit)203,075196,561(30,390)
        
    Total liabilities, convertible preferred shares and shareholders' equity (deficit)$ 207,995$ 203,456$ 32,389
        

    COMPASS PATHWAYS PLC

    Consolidated Statements of Operations and Comprehensive Loss

    (in thousands, except share and per share amounts)

     Three Months

    Ended December 31,
    Twelve Months

    Ended December 31,
     2020201920202019
    OPERATING EXPENSES:    
    Research and development4,5444,57623,36612,563
    General and administrative6,9532,66027,8628390
    General and administrative - fees due to a related party2291165226
    Total operating expenses11,5197,32751,39321,179
    LOSS FROM OPERATIONS:(11,519)(7,327)(51,393)(21,179)
    OTHER INCOME (EXPENSE), NET:    
    Other income(8,433)2131973
    Foreign exchange losses-(148)(11,702)(81
    Fair value change of convertible notes(17)(670)(1,041)(670)
    Fair value change of convertible notes - due to a related party-(469)(730)(469)
    Benefit from R&D tax credit1,0709734,2452,729
    Total other income (expense), net(7,380)(293)(8,909)1,582
    Loss before income taxes(18,899)(7,620)(60,302)(19,597)
    Income tax benefit (expense)93(15)(32)(15)
    Net loss(18,806)(7,635)(60,334)(19,612)
    Other comprehensive (loss) income:    
    Foreign exchange translation adjustment10,91091414,683337
    Comprehensive loss(7,896)(6,721)(45,651)(19,275)
    Net loss per share attributable to ordinary shareholders—basic and diluted$ (0.52)$ (0.90)$ (3.55)$ (2.62)
    Weighted average ordinary shares outstanding—basic and diluted35,912,3338,487,84116,991,6647,476,422


    Primary Logo

    View Full Article Hide Full Article
  4. New York, March 02, 2021 (GLOBE NEWSWIRE) -- London, UK – 2 March 2021

     

    COMPASS Pathways plc (NASDAQ:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter and year ended 31 December 2020, and provide an update on recent business developments, on 9 March 2021.

    The management team will host a conference call at 1:00pm GMT (8.00am ET) on 9 March. The call can be accessed by dialling (833) 665-0659 from the United States, +1 (914) 987-7313 internationally, and 0800 028 8438 from the UK, followed by the conference ID: 5558345.

    The call will also be webcast on the Investors section of the COMPASS Pathways…

    New York, March 02, 2021 (GLOBE NEWSWIRE) -- London, UK – 2 March 2021

     

    COMPASS Pathways plc (NASDAQ:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter and year ended 31 December 2020, and provide an update on recent business developments, on 9 March 2021.

    The management team will host a conference call at 1:00pm GMT (8.00am ET) on 9 March. The call can be accessed by dialling (833) 665-0659 from the United States, +1 (914) 987-7313 internationally, and 0800 028 8438 from the UK, followed by the conference ID: 5558345.

    The call will also be webcast on the Investors section of the COMPASS Pathways website. The webcast will be archived for 30 days.

    -Ends-

    About COMPASS Pathways

    COMPASS Pathways plc (NASDAQ:CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, US. Our vision is a world of mental wellbeing. www.compasspathways.com

     

    Contacts:

     

    COMPASS Pathways

    Media: Tracy Cheung, , +44 7966 309024

    Investors: Stephen Schultz, , +1 401-290-7324

     





    Attachment



    Primary Logo

    View Full Article Hide Full Article
View All COMPASS Pathways Plc News